ANVS - Annovis Bio: Searching For Efficacy In Alzheimer's Disease
2024-04-30 04:49:23 ET
Summary
- On Monday, April 29, Annovis Bio announced their phase 2/3 Alzheimer's Disease trial results, causing stock to drop ~60%.
- Of the five pre-specified efficacy endpoints, only ADAS-Cog11 results were reported in some details, and only from ~28% of the completed patients.
- I take a close look at the results and share my thoughts here.
On Monday, April 29th, Annovis Bio ( ANVS ) announced the topline results from their phase 2/3 Alzheimer's Disease ((AD)) trial. This trial was described as:
Annovis Bio: Searching For Efficacy In Alzheimer's DiseaseThe Phase II/III study was a randomized, double-blind, placebo-controlled trial investigating the efficacy, safety, and tolerability of buntanetap in patients with mild to moderate AD. This was a dose-ranging study where patients received either one of three doses of buntanetap (7.5mg, 15mg, or 30mg) or placebo on top of their standard of care for 12 weeks. In this study, over 700 patients were screened, a total of 353 patients were enrolled, and 325 patients completed the study across 54 sites in the US. The study included mild to moderate AD patients whose Mini Mental State Examination (MMSE) scores at baseline ranged from 14 to 24.